Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab	DNA Virus Infections, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Tumor Virus Infections, adenocarcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, skin disorder, skin neoplasm, viral infectious disease	Recruiting	Phase 2	2026-06-22		NCT07387198

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	34
Prof. Gutzmer, Skin Cancer Center Minden, Johannes-Wesling-Klinikum Minden, Germany	1
Regeneron Pharmaceuticals	238
Universität Duisburg-Essen	21

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
HELIOS Klinikum Erfurt	Erfurt	Germany	5
Johannes Wesling Klinikum Minden	Minden	Germany	5
Klinikum Bielefeld	Bielefeld	Germany	2
Nationales Centrum für Tumorerkrankungen	Heidelberg	Germany	2
Universitätsklinikum Essen	Essen	Germany	16
Universitätsklinikum Frankfurt	Frankfurt am Main	Germany	8
Universitätsklinikum Hamburg-Eppendorf	Hamburg	Germany	7
Universitätsklinikum Köln	Cologne	Germany	8
Universitätsklinikum Leipzig	Leipzig	Germany	23
Universitätsklinikum Mannheim	Mannheim	Germany	1
Universitätsklinikum Regensburg	Regensburg	Germany	6
Universitätsklinikum Tübingen	Tübingen	Germany	15
Universitätsklinikum Würzburg	Würzburg	Germany	22
Universitätsmedizin Mainz	Mainz	Germany	4